L'Ame gauloise : revue bi-mensuelle littéraire, politique et sociale / fondateur administrateur Armand Gilles ; directrice littéraire Gab

11 mars 19231923/03/11 (A9,N125)-1923/03/11

Additional file 12: of Integration of Ixodes ricinus genome sequencing with transcriptome and proteome annotation of the naïve midgut

Combined direct acyclic graphs for the different GO categories “molecular function” (A), “biological process” (B) and “cellular component” (C). (PDF 90 kb

Additional file 13: of Integration of Ixodes ricinus genome sequencing with transcriptome and proteome annotation of the naĂŻve midgut

FDR analysis of mass spectrometry search results. Mass spectrometry search results against concatenated target-decoy databases including protein scores and cumulative FDR. (XLSX 138 kb

Additional file 7: of Integration of Ixodes ricinus genome sequencing with transcriptome and proteome annotation of the naïve midgut

Distribution of annotated sequences by GO categories “molecular function” (A), “biological process” (B) and “cellular component” (C) of level 2 of the combined direct acyclic graph for the annotated transcriptome sequences. The number in brackets represent the number of sequences that are annotated to this GO term. (PDF 495 kb

Anti-B[a]P antibody concentration determined by indirect ELISA and correlation with antibody levels.

<p>To estimate absolute antibody concentrations a standard curve (insert in panel B) was used, that was based on dilution curves (1/200–1/437,400) of different known concentrations (0.01–1 mg/ml, represented by a line for each concentration in panel A) of purified monoclonal antibody against B[a]P (P9E1R4). 1/16,200 dilution (dashed line) was chosen to plot the standard curve (Insert in panel B, R² = 0.9709) and to calculate the antibody concentration. (B) Example of a titration curve of serum antibodies of mice immunised with B[a]P conjugated TT 2 weeks after the fourth injection. Values are presented as mean ± S.E.M of 6 mice per group. (C, D) Correlation between antibody level and [³H]-B[a]P recovery after a single i.p. injection of 2 μg/kg [³H]-B[a]P in individual mice mock immunised and immunised against B[a]P using B[a]P-peptide or B[a]P-TT conjugates. [³H]-B[a]P recovery in the blood (C) and liver (D). The statistical significant relationship between the two variables as shown in C and D was estimated by linear regression.</p

Additional file 4: of Integration of Ixodes ricinus genome sequencing with transcriptome and proteome annotation of the naĂŻve midgut

Homology comparison to Acari genomes (except I. scapularis ). A description of the best match including e-value, identity, bit score and hit length of a homology comparison against all Acari genomes registered at NCBI Genbank at the time of analysis except I. scapularis, namely Dermatophagoides farinae, Metaseiulus occidentalis, Rhipicephalus microplus, Tetranychus urticae and Varroa destructor, are listed for each contig. (XLSX 1023 kb

Immunogenicity of B[a]P-peptide conjugates after tetanus toxoid pre-vaccination.

<p>(A) Endpoint titers (serum dilution reaching 5 times the background) for TT specific IgG antibodies determined by indirect ELISA for sera pre-immunised with tetanus toxoid (TT) followed by B[a]P-peptide or B[a]P-TT conjugate vaccination. (B) B[a]P specific IgG antibodies with and without pre-vaccination. Results are presented for each mouse (○) and median value (–). There was no statistical significant difference between animal with and without pre-vaccination (One way ANOVA procedure followed by Student-Newman-Keuls-t test). (C, D) Antibody selectivity determined by competitive ELISA in sera immunised with B[a]P peptide or B[a]P-TT conjugates with (○) and without (•) tetanus toxoid (TT) pre-vaccination. B[a]P (C) and 7,8-diol-B[a]P (D) were used as competitors to compete for binding of specific antibodies to B[a]P-ovalbumin as the coated antigen. The IC₅₀ (concentration of competitor for 50% inhibition) was calculated to determine the antibody specificity for each tested competitor. The IC₅₀ is inverse correlated to the antibody affinity. Results are presented for each mouse (circle) and median value (–).</p

B[a]P recovery in mice vaccinated against B[a]P and tetanus toxoid.

<p>[³H]-B[a]P recovered in blood 24 h after a single i.p. injection of [³H]-B[a]P (2 µg/kg) in mice immunised with B[a]P-peptide or B[a]P-TT conjugates, with (open bars) or without (closed bars) tetanus toxoid (TT) pre-vaccination. Results are expressed as mean ± S.E.M of 5 mice per group. **p<0.01, ***p<0.001 significant difference from controls (Two Way ANOVA followed by Bonferoni). Control groups are No pre-vaccination (closed bars) or animals without B[a]P vaccination (No vaccination).</p

Antibody titration curves of sera from mice immunised with B[a]P-peptide conjugates.

<p>(A) VNNESSE-variants, (B) FIGITEL-variants, (C) SYFPSV-variants and (D) PNRDIL-variants. Control mice were immunised with B[a]P conjugated to TT-protein (dashed line). Values are mean of 6 mice per group determined by indirect ELISA using heterologous conjugates (B[a]P-ovalbumin) as coated antigen. (E) Serum endpoint titers (serum dilution reaching 5 times the background) of B[a]P specific IgG antibodies of individual mice (○) and median value (–). Groups correspond to a selection of panel A to D. Dashed line represents the endpoint titer for immunisation with tetanus toxoid. (F) Endpoint titers against homologous carrier peptide. For sera with no detectable antibodies endpoint titers were set to 1/200. Results are presented for each mouse (○) and median value (–). ***p<0.001, statistically significant difference from TT immunised mice (One Way ANOVA test followed by Student-Newman-Keuls t-test for multiple comparison).</p

Metabolic activation of B[a]P.

<p>(A) During detoxification a small fraction of B[a]P is activated to 7-8-diol-B[a]P which is further converted to the highly reactive 7,8-dihydroxy-9,10-epoxy-B[a]P (BPDE) the ultimate DNA carcinogen. (B) Chemical structure of the Benzo[a]pyrene butyric acid isomeric mixture (B[a]P-BA), the derivative used for the conjugation to T cell epitope peptides.</p